Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-adjuvanted quadrivalent influenza vaccine vs licensed quadrivalent influenza vaccine in adults 50–64 years
2021-001721-40Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of MF59-adjuvanted quadrivalent influenza vaccine in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoint: Primary Immunogenicity Endpoints. Started Jun 2021; status: completed.
02
Drugs
MF59-adjuvanted quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2021-001721-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001721-40.